NEW YORK (360Dx) – A new mass spectrometry-based assay developed by Quest Diagnostics, which measures the ratio between two peptides associated with Alzheimer's disease, is demonstrating increased specificity and sensitivity in diagnosing the ailment in research studies, according to the company.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.